Dutton Associates Announces Investment Opinion: Oragenics Initial Rating At Speculative Buy By Dutton Associates.

EL DORADO HILLS, Calif. -- Dutton Associates initiates coverage of Oragenics, Inc. (AMEX:ONI) with a Speculative Buy rating and a price target, subject to obtaining adequate financing, of $3.75. The 21-page report by Dutton senior analyst Wayne T. Lottinville, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias and other leading financial portals. E[acute accent]Oragenics is an early-stage biopharmaceutical company with several promising products in its product pipeline. These include a natural, orally available compound with an excellent safety profile that shows great promise in treating obesity; an advanced antibiotic against which none of the bacteria tested have yet been able to develop genetically stable resistance; "Disruptive" oral health therapies, including one that quickly and easily eliminates the major cause of tooth decay; and a pioneering way to synthesize useful quantities of difficult-to-produce bioactive peptides, including small-molecule antibiotics. If successfully commercialized, several could result in annual sales in excess of $1 billion. Successful progress in any one of the Company's development programs could add $100 million or more to Oragenics' market capitalization. The most significant impediment to Oragenics' progress is its financial constraints. The Company must secure adequate financing to continue developing its technology. Jeffrey Hillman, D.M.D., Ph.D., confounded Oragenics and serves as the Company's chief scientific officer. The Company's current pipeline is largely the result of Dr. Hillman's 25 years of research at the Forsyth Research Institute, affiliated with Harvard University in Boston, and at the University of Florida. The conclusions of this report assume that Oragenics will ...